Cytek Biosciences Reports Substantial Net Loss and Negative Operating Cash Flow for FY2025

summarizeSummary

Cytek Biosciences reported a significant increase in net loss to $66.5 million for fiscal year 2025, alongside a shift to negative operating cash flow and a decline in gross margin, despite a slight revenue increase.

check_boxKey Events

• Substantial Increase in Net Loss

  Net loss for fiscal year 2025 surged to $66.5 million, a significant increase from $6.0 million in 2024, largely due to a $33.1 million valuation allowance against deferred tax assets.

• Operating Cash Flow Turns Negative

  Operating activities consumed $4.7 million in cash for 2025, a reversal from the $25.4 million generated in 2024.

• Gross Margin Decline Amidst Stagnant Revenue Growth

  Overall gross margin decreased to 52% in 2025 from 55% in 2024, with total revenue growing only 1% year-over-year, driven by a 6% decline in product revenue.

• Remediation of Material Weaknesses in Internal Controls

  The company successfully remediated previously identified material weaknesses in its internal control over financial reporting as of December 31, 2025.

auto_awesomeAnalysis

Cytek Biosciences reported a significant deterioration in its financial performance for fiscal year 2025. The company's net loss widened substantially to $66.5 million, primarily driven by a $33.1 million valuation allowance against deferred tax assets. This marks a sharp decline from the $6.0 million net loss in 2024. Furthermore, operating cash flow turned negative, moving from a positive $25.4 million in 2024 to a negative $4.7 million in 2025, indicating increased cash burn from operations. While total revenue saw a modest 1% increase, product revenue declined by 6%, offset by a 21% rise in service revenue. The overall gross margin also decreased from 55% to 52%. On a positive note, the company announced the successful remediation of previously disclosed material weaknesses in internal control over financial reporting as of December 31, 2025. The $150 million at-the-market (ATM) offering program expired in August 2025 without any shares being sold, resulting in $0.7 million in expensed transaction costs. The company also continued its share repurchase program, buying back $15.1 million in 2025, with $35.0 million remaining authorized under the program which expired on December 31, 2025. An ongoing patent infringement lawsuit by Beckman Coulter, Inc. remains a significant legal overhang, with a trial scheduled for August 2026.